UBS Maintains Buy on Repligen, Lowers Price Target to $170
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Elizabeth Garcia maintains a Buy rating on Repligen (NASDAQ:RGEN) but lowers the price target from $210 to $170.
November 01, 2023 | 7:12 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
UBS maintains a Buy rating on Repligen but lowers the price target from $210 to $170.
The news is directly related to Repligen. While the maintained Buy rating is positive, the lowered price target might indicate a slower growth expectation, which could have a neutral to slightly negative impact on the stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100